Considerations for Subgroup Analyses in Cluster-Randomized Trials Based on Aggregated Individual-Level Predictors

被引:1
|
作者
Williamson, Brian D. [1 ,2 ,3 ]
Coley, R. Yates [1 ,3 ]
Hsu, Clarissa [4 ]
Mccracken, Courtney E. [5 ]
Cook, Andrea J. [1 ,3 ]
机构
[1] Kaiser Permanente Washington Hlth Res Inst, Biostat Div, Seattle, WA 98101 USA
[2] Fred Hutchinson Canc Ctr, Vaccine & Infect Dis Div, Seattle, WA 98109 USA
[3] Univ Washington, Dept Biostat, Seattle, WA 98195 USA
[4] Kaiser Permanente Washington Hlth Res Inst, Investigat Sci Div, Seattle, WA USA
[5] Kaiser Permanente Georgia, Ctr Res & Evaluat, Atlanta, GA USA
关键词
Heterogeneity of treatment effects; Subgroup analyses; Cluster-randomized trials; Ecological studies; Health disparities; BOOT CAMP TRANSLATION; EPIDEMIOLOGY; RACE; INTERSECTIONALITY; HETEROGENEITY; CHALLENGES; COMMUNITY; BIAS;
D O I
10.1007/s11121-023-01606-1
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
In research assessing the effect of an intervention or exposure, a key secondary objective often involves assessing differential effects of this intervention or exposure in subgroups of interest; this is often referred to as assessing effect modification or heterogeneity of treatment effects (HTE). Observed HTE can have important implications for policy, including intervention strategies (e.g., will some patients benefit more from intervention than others?) and prioritizing resources (e.g., to reduce observed health disparities). Analysis of HTE is well understood in studies where the independent unit is an individual. In contrast, in studies where the independent unit is a cluster (e.g., a hospital or school) and a cluster-level outcome is used in the analysis, it is less well understood how to proceed if the HTE analysis of interest involves an individual-level characteristic (e.g., self-reported race) that must be aggregated at the cluster level. Through simulations, we show that only individual-level models have power to detect HTE by individual-level variables; if outcomes must be defined at the cluster level, then there is often low power to detect HTE by the corresponding aggregated variables. We illustrate the challenges inherent to this type of analysis in a study assessing the effect of an intervention on increasing COVID-19 booster vaccination rates at long-term care centers.
引用
收藏
页码:421 / 432
页数:12
相关论文
共 50 条
  • [21] Are Donation-Based Measures of Ideology Valid Predictors of Individual-Level Policy Preferences?
    Bonica, Adam
    JOURNAL OF POLITICS, 2019, 81 (01): : 327 - 333
  • [22] Statistical Power for Causally Defined Indirect Effects in Group-Randomized Trials With Individual-Level Mediators
    Kelcey, Benjamin
    Dong, Nianbo
    Spybrook, Jessaca
    Cox, Kyle
    JOURNAL OF EDUCATIONAL AND BEHAVIORAL STATISTICS, 2017, 42 (05) : 499 - 530
  • [23] Methods for the estimation of direct and indirect vaccination effects by combining data from individual- and cluster-randomized trials
    Wang, Rui
    Cen, Mengqi
    Huang, Yunda
    Qian, George
    Dean, Natalie E.
    Ellenberg, Susan S.
    Fleming, Thomas R.
    Lu, Wenbin
    Longini, Ira M.
    STATISTICS IN MEDICINE, 2024, 43 (08) : 1627 - 1639
  • [24] Risk of Bias in Cluster Randomised Controlled Trials of Individual-Level Interventions: Protocol for a Semi-Structured Interview Study
    Easter, Christina
    Kristunas, Caroline
    Hemming, Karla
    Greenfield, Sheila
    INTERNATIONAL JOURNAL OF QUALITATIVE METHODS, 2022, 21
  • [25] Randomized controlled trials of individual-level, population-level, and multilevel interventions for preventing sexually transmitted infections: What has worked?
    Manhart, LE
    Holmes, KK
    JOURNAL OF INFECTIOUS DISEASES, 2005, 191 : S7 - S24
  • [26] Evaluating performance of covariate-constrained randomization (CCR) techniques under misspecification of cluster-level variables in cluster-randomized trials
    Organ, Madeleine
    Tandon, S. Darius
    Diebold, Alicia
    Johnson, Jessica K.
    Yeh, Chen
    Ciolino, Jody D.
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2021, 22
  • [27] Comparing Methods to Generalize Randomized Clinical Trials without Individual-Level Data for the Real-World Target Population
    Hong, Jin-Liern
    Webster-Clark, Michael
    Funk, Michele Jonsson
    Dempster, Sara
    Sturmer, Til
    Cole, Stephen R.
    LoCasale, Robert
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 32 - 33
  • [28] Addressing Methodologic Challenges and Minimizing Threats to Validity in Synthesizing Findings from Individual-Level Data Across Longitudinal Randomized Trials
    Ahnalee Brincks
    Samantha Montag
    George W. Howe
    Shi Huang
    Juned Siddique
    Soyeon Ahn
    Irwin N. Sandler
    Hilda Pantin
    C. Hendricks Brown
    Prevention Science, 2018, 19 : 60 - 73
  • [29] Addressing Methodologic Challenges and Minimizing Threats to Validity in Synthesizing Findings from Individual-Level Data Across Longitudinal Randomized Trials
    Brincks, Ahnalee
    Montag, Samantha
    Howe, George W.
    Huang, Shi
    Siddique, Juned
    Ahn, Soyeon
    Sandler, Irwin N.
    Pantin, Hilda
    Brown, C. Hendricks
    PREVENTION SCIENCE, 2018, 19 (01) : S60 - S73
  • [30] Incorrect Analyses of Cluster-Randomized Trials that Do Not Take Clustering and Nesting into Account Likely Lead to p-Values that Are Too Small
    Golzarri-Arroyo, Lilian
    Oakes, J. Michael
    Brown, Andrew W.
    Allison, David B.
    CHILDHOOD OBESITY, 2020, 16 (02) : 65 - 66